SCHEMBL212464

SCHEMBL212464

CC(=O)ON=C1CCCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
FAAH O00519 1/20 0.47
ABHD16A O95870 1/20 0.47
PLA2G7 Q13093 1/20 0.47
NCEH1 Q6PIU2 1/20 0.47
DAGLB Q8NCG7 1/20 0.47
DAGLA Q9Y4D2 1/20 0.47
GAA P10253 1/20 0.46
ALDH1A1 P00352 1/20 0.43
TSHR P16473 1/20 0.35
CASP1 P29466 1/20 0.35
KDM4E B2RXH2 3/20 0.32
RXFP1 Q9HBX9 1/20 0.32
ESR1 P03372 1/20 0.32
PGR P06401 1/20 0.32
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL213364 0.98 MEN1 (0.50) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL215531 0.98 MEN1 (0.50) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL214510 0.98 MEN1 (0.50) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL212465 0.98 MEN1 (0.50) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL212565 0.98 MEN1 (0.50) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL2045395 0.90 RAB9A (0.38) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL2044667 0.86 RAB9A (0.38) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL2044665 0.86 RAB9A (0.38) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL9900514 0.82 RAB9A (0.34) RAB9ASMN1; SMN2NPC1MEN1KMT2A
SCHEMBL2045183 0.81 MAPT (0.34) RAB9ASMN1; SMN2NPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US claimed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US claimed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US claimed
US-10287419-B2 Rubber composition and vulcanization aid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-05-14 US disclosed
US-20170130028-A1 RUBBER COMPOSITION AND VULCANIZATION AID SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-11 US disclosed
US-20170130028-A1 RUBBER COMPOSITION AND VULCANIZATION AID SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-11 US disclosed
US-8541509-B2 Polymers functionalized with protected oxime compounds BRIDGESTONE CORPORATION (JP) 2013-09-24 US disclosed
US-20120077941-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2012-03-29 US disclosed
US-8088868-B2 oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis BRIDGESTONE CORPORATION (JP) 2012-01-03 US disclosed
US-20080146745-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS BRIDGESTONE CORPORATION (JP) 2008-06-19 US disclosed
EP-0926135-B1 Processes for producing alpha-aminonitrile derivatives and alpha-amino acids DAICEL CHEM (JP) 2002-06-05 EP disclosed
US-6100419-A Processes for producing α-aminonitrile derivatives and α-amino acids DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2000-08-08 US disclosed
EP-0926135-A2 Processes for producing alpha-aminonitrile derivatives and alpha-amino acids Daicel Chemical Industries, Ltd. (JP) 1999-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287419-B2 Rubber composition and vulcanization aid CCNA1, RCN1, RER1 RAB9A 3109/4885SMN1; SMN2 3110/4885NPC1 1918/4885
US-20170130028-A1 RUBBER COMPOSITION AND VULCANIZATION AID CCNA1, RCN1, RER1 RAB9A 3109/4885SMN1; SMN2 3110/4885NPC1 1918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.